Misinformation, Trust, and Use of Ivermectin and Hydroxychloroquine for COVID-19

被引:7
|
作者
Perlis, Roy H. [1 ,2 ,3 ,4 ]
Trujillo, Kristin Lunz [5 ,6 ]
Green, Jon [5 ]
Safarpour, Alauna [5 ,6 ]
Druckman, James N. [7 ]
Santillana, Mauricio [5 ]
Ognyanova, Katherine [8 ]
Lazer, David [5 ]
机构
[1] Massachusetts Gen Hosp, 185 Cambridge St,Sixth Floor, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA
[3] Harvard Med Sch, Dept Psychiat, Boston, MA USA
[4] JAMA Network Open Perlis, Chicago, IL 60611 USA
[5] Northeastern Univ, Dept Polit Sci, Boston, MA USA
[6] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA
[7] Northwestern Univ, Dept Polit Sci, Evanston, IL USA
[8] Rutgers State Univ, Sch Commun & Informat, Dept Commun, New Brunswick, NJ USA
来源
JAMA HEALTH FORUM | 2023年 / 4卷 / 09期
基金
美国国家科学基金会;
关键词
D O I
10.1001/jamahealthforum.2023.3257
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Importance The COVID-19 pandemic has been notable for the widespread dissemination of misinformation regarding the virus and appropriate treatment.Objective To quantify the prevalence of non-evidence-based treatment for COVID-19 in the US and the association between such treatment and endorsement of misinformation as well as lack of trust in physicians and scientists.Design, Setting, and Participants This single-wave, population-based, nonprobability internet survey study was conducted between December 22, 2022, and January 16, 2023, in US residents 18 years or older who reported prior COVID-19 infection.Main Outcome and Measure Self-reported use of ivermectin or hydroxychloroquine, endorsing false statements related to COVID-19 vaccination, self-reported trust in various institutions, conspiratorial thinking measured by the American Conspiracy Thinking Scale, and news sources.Results A total of 13 438 individuals (mean [SD] age, 42.7 [16.1] years; 9150 [68.1%] female and 4288 [31.9%] male) who reported prior COVID-19 infection were included in this study. In this cohort, 799 (5.9%) reported prior use of hydroxychloroquine (527 [3.9%]) or ivermectin (440 [3.3%]). In regression models including sociodemographic features as well as political affiliation, those who endorsed at least 1 item of COVID-19 vaccine misinformation were more likely to receive non-evidence-based medication (adjusted odds ratio [OR], 2.86; 95% CI, 2.28-3.58). Those reporting trust in physicians and hospitals (adjusted OR, 0.74; 95% CI, 0.56-0.98) and in scientists (adjusted OR, 0.63; 95% CI, 0.51-0.79) were less likely to receive non-evidence-based medication. Respondents reporting trust in social media (adjusted OR, 2.39; 95% CI, 2.00-2.87) and in Donald Trump (adjusted OR, 2.97; 95% CI, 2.34-3.78) were more likely to have taken non-evidence-based medication. Individuals with greater scores on the American Conspiracy Thinking Scale were more likely to have received non-evidence-based medications (unadjusted OR, 1.09; 95% CI, 1.06-1.11; adjusted OR, 1.10; 95% CI, 1.07-1.13).Conclusions and Relevance In this survey study of US adults, endorsement of misinformation about the COVID-19 pandemic, lack of trust in physicians or scientists, conspiracy-mindedness, and the nature of news sources were associated with receiving non-evidence-based treatment for COVID-19. These results suggest that the potential harms of misinformation may extend to the use of ineffective and potentially toxic treatments in addition to avoidance of health-promoting behaviors.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Misinformation, Trust, and Use of Ivermectin and Hydroxychloroquine for COVID-19 ( vol 4 , e233257 , 2023)
    Perlis, R. H.
    Trujillo, K. Lunz
    Green, J.
    [J]. JAMA HEALTH FORUM, 2023, 4 (10):
  • [2] Hydroxychloroquine, azithromycin and ivermectin: treatments not recommended for Covid-19
    Buxeraud, Jacques
    [J]. ACTUALITES PHARMACEUTIQUES, 2023, 62 (627): : 4 - 4
  • [3] Ivermectin for COVID-19; to use or not to use?
    Morimoto, Yasuhiro
    [J]. ANAESTHESIA PAIN & INTENSIVE CARE, 2021, 25 (05) : 566 - 568
  • [4] Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
    Patri, Angela
    Fabbrocini, Gabriella
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (06) : E221 - E221
  • [5] The Use of Ivermectin in the Treatment of COVID-19
    Shukla, Ajay Kumar
    Misra, Saurav
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 (06) : 1554 - 1554
  • [6] The Use of Ivermectin in the Treatment of COVID-19
    Ajay Kumar Shukla
    Saurav Misra
    [J]. Journal of General Internal Medicine, 2023, 38 : 1554 - 1554
  • [7] The use of Hydroxychloroquine in the Treatment of COVID-19
    Tecen-Yucel, Kamer
    Kara, Emre
    Demirkan, Kutay
    Unal, Serhat
    [J]. FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, 2020, 25 (03): : 283 - 291
  • [8] Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
    Choudhary, R.
    Sharma, A. K.
    [J]. NEW MICROBES AND NEW INFECTIONS, 2020, 35
  • [9] The impact of COVID-19 misinformation and trust in institutions on preventive behaviors
    Lee, Stella Juhyun
    Lee, Chul-Joo
    Hwang, Hyunjung
    [J]. HEALTH EDUCATION RESEARCH, 2023, 38 (01) : 95 - 105
  • [10] IVERMECTIN AND ITS POSSIBLE USE IN COVID-19
    Tavera Lits, Ruth Ysabel
    Hernandez Pozo, Clara Elisa
    Morillo Cano, Julio Rodrigo
    Alonzo Pico, Olga Mireya
    [J]. REVISTA UNIVERSIDAD Y SOCIEDAD, 2021, 13 (06): : 560 - 565